Updates are available Correction dated 2025-02-27
Click to view Correction: https://doi.org/10.1038/s41409-025-02534-0
-
Authors
Meyers, Gabrielle https://orcid.org/0000-0001-7821-8745
Hamadani, Mehdi https://orcid.org/0000-0001-5372-510X
Martens, Michael https://orcid.org/0000-0003-3799-681X
Ali, Haris https://orcid.org/0000-0002-9728-7292
Chevallier, Patrice https://orcid.org/0000-0003-3142-5581
Choe, Hannah
Harris, Andrew C. https://orcid.org/0000-0002-4538-8817
Holler, Ernst https://orcid.org/0000-0003-2295-2187
van Hooren, Eric
Klaassen, Willem
Leifer, Eric
van Oosterhout, Ypke
Perez, Lia
Pusic, Iskra
Stelljes, Matthias
van der Velden, Walter https://orcid.org/0000-0002-7002-9701
Ammatuna, Emanuele
Beauvais, David https://orcid.org/0000-0003-1866-828X
Cornillon, Jérôme
Maziarz, Richard T. https://orcid.org/0000-0002-8184-7099
Schetelig, Johannes https://orcid.org/0000-0002-2780-2981
Romeril, Jennifer
MacMillan, Margaret L. https://orcid.org/0000-0002-0755-0852
Levine, John E. https://orcid.org/0000-0002-5611-7828
Socié, Gérard https://orcid.org/0000-0002-2114-7533
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (U10HL069294, U24HL138660)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute
Xenikos BV and National Cancer Institute
- License Information
-
More Information
Article History
Received: 17 August 2023
Revised: 7 September 2023
Accepted: 14 September 2023
First Online: 25 September 2023
Change Date: 20 February 2025
Change Type: Update
Change Details: The original online version of this article was revised: In this article the grant number has been updated to U24HL138660.
Change Date: 27 February 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41409-025-02534-0
Competing interests
: EvH, WK and YvO are employees of Xenikos and own equity in Xenikos. MH: Consultancy: Incyte Corporation, MorphoSys, SeaGen, Gamida Cell, Novartis, Legend Biotech, Kadmon, ADC Therapeutics; Omeros, CRISPR, Genmab, Kite, BMS, Caribou, Abbvie. Speaker’s Bureau: Sanofi Genzyme, AstraZeneca, BeiGene, ADC Therapeutics, Kite. Data Monitoring Committee: Myeloid Therapeutics, Inc, Genentech. HC: Research funding: Opna, Scientific Advisory Board: Incyte. EH: Scientific Advisory Board: Novartis, Medac, Pharmabiome and Maat Pharma. RTM Consultancy: Novartis, Artiva, Incyte, Kite, BMS. Research funding: Novartis, Allovir, and Orca. Data Safety Monitoring Board Service: Novartis, Century Therapeutics, VOR Pharma and Athersys. ACH: Consultancy: Janssen and Incyte. GS: Scientific Advisory Board: Novartis, Incyte, AlloVIR, Sanofi. JEL: Research funding: Genentech, Incyte, and Mesoblast, Consultancy: Bluebird Bio, Editas, Equillium, Incyte, Inhibrx, Kamada, Mesoblast, Sanofi, and X4 Pharmaceuticals, Royalties: Viracor (GVHD biomarker patent). DB: Consultancy: BMS, Gilead.
